China Shenghuo Announces Additional Roll-Out of ’12 Ways’ Cosmetics Products to Watsons Stores
Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) (“China Shenghuo” or
the “Company”), today announced that the Company is expanding its herbal-based
“12 Ways” cosmetics products into additional Watsons Personal Stores in
strategic markets in Mainland China.
The Company has already launched its “12 Ways” brand of cosmetics products
to eleven stores of the Watsons Your Personal Store (“Watsons Stores”) in
seven cities in
retailer in
enter an additional eleven Watsons stores in eight different cities including
additional eleven stores by early 2009 to include cities such as
Kunming.
“Watsons Stores is an excellent entry point for China Shenghuo to
introduce our high-end ’12 Ways’ cosmetics products,” Mr. Gui Hua Lan, Chief
Executive Officer of China Shenghuo, said. “We believe our partnership with
Watsons and our anticipated success will give us a greater marketing platform
to continue our expansion into other markets.”
“12 Ways” cosmetics contain natural ingredients including herbal anti-
irritants and anti-oxidants as well as Sanchi, which is the key ingredient for
the Company’s pharmaceutical products. Introduced in September of 2007, “12
Ways” is the Company’s Sanchi-based cosmetics product lines that feature
products varying from eye, face and skin creams to shampoos. The Company has
already launched a total of 37 different cosmetics products for sale. The “12
Ways” products that are being rolled out to Watsons include Panax Notoginseng
Moisture Series, Danshen Spots Fade Series, Yunnan Bamboo Anti-Acne Series,
Snow Poria Whitening Series, Sunscreen Series and Eye Care Series.
About Watsons Your Personal Store
Watsons Your Personal Store (“Watsons Stores”) is one of the largest
health and beauty retail chains in
in thirteen different markets include
1,600 outlets. For additional detail regarding Watsons and its corporate
parent A.S. Watson Group, please see http://www.aswatson.com .
About China Shenghuo
Founded in 1995, China Shenghuo is a specialty pharmaceutical company that
focuses on the research, development, manufacture and marketing of Sanchi-
based medicinal and pharmaceutical, nutritional supplement and cosmetic
products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co.,
Ltd., it owns thirty SFDA (State Food and Drug Administration) approved
medicines, including the flagship product Xuesaitong Soft Capsules, which has
already been listed in the Insurance Catalogue. At present, China Shenghuo
incorporates a sales network of agencies and representatives throughout
which markets Sanchi-based traditional Chinese medicine to hospitals and drug
stores as prescription and OTC drugs primarily for the treatment of
cardiovascular, cerebrovascular and peptic ulcer disease. The Company also
exports medicinal products to Asian countries such as
Safe Harbor Statement
This press release may contain certain “forward-looking statements,” as
defined in
that involve a number of risks and uncertainties. There can be no assurance
that such statements will prove to be accurate, and the actual results and
future events could differ materially from management’s current expectations.
Such factors include, but are not limited to, risks of litigation and
governmental or other regulatory inquiry or proceedings arising out of or
related to any of the matters described in recent press releases, including
arising out of the restatement of the Company’s financial statements; the
Company’s continuing ability to satisfy any requirements which may be
prescribed by the Exchange for continued listing on the Exchange; potential
adverse effects to the Company’s financial condition, results of operations or
prospects as a result of possible changes to or restatements of prior period
financial statements; risks arising from potential weaknesses or deficiencies
in the Company’s internal control over financial reporting; the Company’s
reliance on one supplier for Sanchi; the possible effect of adverse publicity
on the Company’s business, including possible contract cancellation; the
Company’s ability to develop and market new products; the Company’s ability to
establish and maintain a strong brand; the Company’s continued ability to
obtain and maintain all certificates, permits and licenses required to open
and operate retail specialty counters to offer its cosmetic products and
conduct business in
rights; market acceptance of the Company’s products; changes in the laws of
the Company of complying with current and future governmental regulations; the
impact of any changes in governmental regulations on the Company’s operations;
general economic conditions; and other factors detailed from time to time in
the Company’s filings with the United States Securities and Exchange
Commission and other regulatory authorities. The Company undertakes no
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For more information, please contact:
China Shenghuo Pharmaceutical Holdings, Inc.
Mr. Changhua Mu
Securities Affairs Representative
Tel: +86-871-728-2698
Email: c.mu@chinashenghuo.net
Grayling Global
Eddie Cheung
Investor Relations
Tel: +1-646-284-9414
Email: echeung@hfgcg.com
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.